Triple Negative Breast Neoplasms

"Triple Negative Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Descriptor ID	D064726
MeSH Number(s)	C04.588.180.788 C17.800.090.500.788
Concept/Terms	Triple Negative Breast Neoplasms Triple Negative Breast Neoplasms ER-Negative PR-Negative HER2-Negative Breast Neoplasms ER Negative PR Negative HER2 Negative Breast Neoplasms Triple-Negative Breast Cancer Breast Cancer, Triple-Negative Breast Cancers, Triple-Negative Triple-Negative Breast Cancers Triple-Negative Breast Neoplasm Breast Neoplasm, Triple-Negative Breast Neoplasms, Triple-Negative Triple Negative Breast Neoplasm Triple-Negative Breast Neoplasms ER-Negative PR-Negative HER2-Negative Breast Cancer ER Negative PR Negative HER2 Negative Breast Cancer Triple Negative Breast Cancer

Below are MeSH descriptors whose meaning is more general than "Triple Negative Breast Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Breast Neoplasms [C04.588.180]
Triple Negative Breast Neoplasms [C04.588.180.788]
Skin and Connective Tissue Diseases [C17]
Skin Diseases [C17.800]
Breast Diseases [C17.800.090]
Breast Neoplasms [C17.800.090.500]
Triple Negative Breast Neoplasms [C17.800.090.500.788]

Below are MeSH descriptors whose meaning is related to "Triple Negative Breast Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Triple Negative Breast Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Triple Negative Breast Neoplasms" by people in this website by year, and whether "Triple Negative Breast Neoplasms" was a major or minor topic of these publications.

Bar chart showing 10 publications over 5 distinct years, with a maximum of 3 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Total
2013	1	1
2014	2	2
2015	2	2
2016	2	2
2017	3	3

Below are the most recent publications written about "Triple Negative Breast Neoplasms" by people in Profiles.

Maher CM, Thomas JD, Haas DA, Longen CG, Oyer HM, Tong JY, Kim FJ. Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1. Mol Cancer Res. 2018 02; 16(2):243-255.

View in: PubMed
Yuan X, Kho D, Xu J, Gajan A, Wu K, Wu GS. ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells. Oncotarget. 2017 Mar 28; 8(13):21626-21638.

View in: PubMed
Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, Gradishar WJ, Giles FJ. Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. Cancer Treat Rev. 2017 Feb; 53:111-119.

View in: PubMed
Joneja U, Vranic S, Swensen J, Feldman R, Chen W, Kimbrough J, Xiao N, Reddy S, Palazzo J, Gatalica Z. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol. 2017 Mar; 70(3):255-259.

View in: PubMed
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016 08 01; 22(15):3764-73.

View in: PubMed
Tonsing-Carter E, Bailey BJ, Saadatzadeh MR, Ding J, Wang H, Sinn AL, Peterman KM, Spragins TK, Silver JM, Sprouse AA, Georgiadis TM, Gunter TZ, Long EC, Minto RE, Marchal CC, Batuello CN, Safa AR, Hanenberg H, Territo PR, Sandusky GE, Mayo LD, Eischen CM, Shannon HE, Pollok KE. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. Mol Cancer Ther. 2015 Dec; 14(12):2850-63.

View in: PubMed
Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clin Cancer Res. 2016 Jan 1; 22(1):26-33.

View in: PubMed
Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.

View in: PubMed
Grieb BC, Chen X, Eischen CM. MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Mol Cancer Res. 2014 Sep; 12(9):1216-24.

View in: PubMed
Chang B, Sokhn J, James E, Abu-Khalaf M. Prolonged progression-free survival in a patient with triple-negative breast cancer metastatic to the liver after chemotherapy and local radiation therapy. Clin Breast Cancer. 2014 Apr; 14(2):e61-4.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement